Jak Inhibitor Deuruxolitinib Shows Encouraging Hair Re-Growth In Alopecia Areata

The THRIVE-AA1 trial evaluated the efficacy of the JAK1/2 inhibitor deuruxolitinib in treating alopecia areata, involving 706 adult patients with significant hair loss. Participants were randomized to receive either a placebo or deuruxolitinib at doses of 8 mg or 12 mg twice daily. By week 24, 29.6% of those on 8 mg and 41.5% on 12 mg achieved a SALT score of 20 or less, indicating substantial hair regrowth compared to placebo. Significant improvements were noted as early as week 8. The treatment was mostly well tolerated, with over 95% of adverse events being mild-to-moderate. The study concluded that deuruxolitinib showed encouraging efficacy for moderate-to-severe alopecia areata.